Refuge Biotechnologies

Refuge Biotechnologies is a cancer immunotherapy company with a mission to design intelligent cell therapies to fight cancer. Leveraging synthetic biology and gene engineering, the company aims to unlock the full potential of cell therapies. Refuge creates cell therapies that have the ability to sense their surroundings and conditionally activate or repress multiple genes simultaneously, leading to more potent and targeted treatments beyond a single target and function. Founded in 2015 and headquartered in the United States, Refuge Biotechnologies recently secured a $25.00M Series B investment on 02 May 2018. The investment came from a group of notable investors including DHVC, WuXi Healthcare Ventures, 3E Bioventures Capital, Sequoia China, ShangBay Capital, 3SBio Inc., Ocean Pine Healthcare Fund, and Sangel Capital. With a focus on the biotechnology and health care industries, Refuge Biotechnologies is poised to make significant advancements in the field of cancer treatment through its innovative approach to cell therapy.